

Art Unit: 1625

DETAILED ACTION

1. The request for reconsideration filed on Aug. 30, 2004 has been considered carefully.

Based on the restriction and species election, the subject matter of claim 30 wherein R' is R1 and R1 is the scope of claim 28, nonheterocyclic, is examined.

One method of treating HIV in vitro in cell is rejoined with the elected compounds. The remaining compounds and compositions of claims 1-29, 32, 34-95 and the remaining subject matter of claim 30, not reading on the elected compounds or in vitro inhibition of retroviral protease activity are withdrawn from consideration per 37 CFR 1.142(b).

Claims 30 R' is alkyl, thioalkyl, alkylthioalkyl, alkenyl, alkynyl and cycloalkyl and claims 31, 33 reading on the elected claim 30 are examined.

2. *Examiner's Amendment*


Authorization for this examiner's amendment was given in a telephone interview with Mr. Benjamin Spehlmann on April 20, 2005.

Claims ~~1-99~~ have been canceled.

Applicants have limited the claims to the elected invention and replacing the pending claims with the newly added claims 100-104. Rejoining only the method for inhibiting retroviral protease in cells. Support for the instant amendment are found in claims 19, 28, 30-33 as originally filed.

Art Unit: 1625

Claim 100 (New): A compound represented by the formula



wherein

R' represents a radical selected from the group consisting of alkyl, aryl, and arylalkyl;

t is 0 or 1;

R^1 represents a radical selected from the group consisting of a hydrogen radical, $-\text{CH}_2\text{SO}_2\text{NH}_2$, $-\text{CO}_2\text{CH}_3$, $-\text{CH}_2\text{CO}_2\text{CH}_3$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{O})\text{NHCH}_3$, $-\text{C}(\text{O})\text{N}(\text{CH}_3)_2$, $-\text{CH}_2\text{C}(\text{O})\text{NHCH}_3$, $-\text{CH}_2\text{C}(\text{O})\text{N}(\text{CH}_3)_2$, alkyl, alkylthioalkyl, thioalkyl, the corresponding sulfoxide and sulfone derivatives of alkylthioalkyl and thioalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, cycloalkyl, and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine, and the corresponding sulfoxide and sulfone derivatives of S-methyl cysteine, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine, phenylalanine, ornithine, histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine;


Y' represents O, S, and NR^3 , wherein R^3 represents a radical selected from the group consisting of a hydrogen radical, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;

R^6 represents a hydrogen radical or an alkyl radical; and

R^{20} and R^{21} independently represent radicals as defined for R^1 .

Art Unit: 1625

Claim 101 (New): A compound of claim 100 having the formula



Claim 102 (New): A pharmaceutical composition comprising a compound of claim 100 and a pharmaceutical carrier.

Claim 103 (New): A pharmaceutical composition comprising a compound of claim 100 and pharmaceutical carriers.

Claim 104 (New): A method of inhibiting a retroviral protease in vitro comprising administering a protease inhibiting amount of a compound of claim 100 to a cell.